Phase II study of irinotecan and mitomycin C in 5-fluorouracil-pretreated patients with advanced colorectal and gastric cancer

Απλή σελίδα τεκμηρίου
dc.contributor.authorBamias, A.en
dc.contributor.authorPapamichael, D.en
dc.contributor.authorSyrigos, K.en
dc.contributor.authorPavlidis, N.en
dc.date.accessioned2015-11-24T18:58:51Z
dc.date.available2015-11-24T18:58:51Z
dc.identifier.issn1120-009X-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/19318
dc.rightsDefault Licence-
dc.subjectAdenocarcinoma/*drug therapy/mortality/pathologyen
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAntineoplastic Combined Chemotherapy Protocols/*administration & dosage/*adverseen
dc.subjecteffectsen
dc.subjectCamptothecin/administration & dosage/adverse effects/*analogs & derivativesen
dc.subjectChi-Square Distributionen
dc.subjectColorectal Neoplasms/*drug therapy/mortality/pathologyen
dc.subjectDose-Response Relationship, Drugen
dc.subjectDrug Administration Scheduleen
dc.subjectDrug Toxicityen
dc.subjectFemaleen
dc.subjectFluorouracil/administration & dosage/adverse effectsen
dc.subjectFollow-Up Studiesen
dc.subjectHumansen
dc.subjectMaleen
dc.subjectMaximum Tolerated Doseen
dc.subjectMiddle Ageden
dc.subjectMitomycin/administration & dosage/adverse effectsen
dc.subjectNeoplasm Stagingen
dc.subjectOdds Ratioen
dc.subjectProbabilityen
dc.subjectRisk Assessmenten
dc.subject*Salvage Therapyen
dc.subjectStomach Neoplasms/*drug therapy/mortality/pathologyen
dc.subjectSurvival Analysisen
dc.titlePhase II study of irinotecan and mitomycin C in 5-fluorouracil-pretreated patients with advanced colorectal and gastric canceren
heal.abstractThe aim of this phase II study was to investigate the tolerance and efficacy of a second-line irinotecan/mitomycin C combination in patients with advanced gastric or colorectal cancer, pretreated with 5-fluorouracil. Forty patients who had received 5-fluorouracil-based chemotherapy for advanced disease or adjuvant 5-fluorouracil treatment were enrolled. Chemotherapy consisted of irinotecan 125 mg/m2 and mitomycin C 5 mg/m2, given every 2 weeks. Treatment was continued until progression or limiting toxicity occurred. Five partial responses (12.5%), 22 cases of stable disease (55%) and 13 of progression (32.5%) were registered, giving an overall response rate of 12.5% [95% confidence interval (CI), 4.2-26.8%] and an overall control of tumor growth in 67.5% (95% CI, 50.8-81.4%) of patients. Median progression-free survival was 5 months, median survival time 8 months, and 1-year probability of survival was 21.6%. Diarrhea and neutropenia affected 25% and 12.5% of patients respectively, with only 7.5% experiencing grade 3-4 toxicity. There were no chemotherapy-related deaths or hospitalizations. This combination regimen was shown to be moderately effective with substantially lower toxicity than irinotecan monotherapy in 5-fluorouracil-pretreated patients with advanced gastric or colorectal cancer. It may represent an attractive option in patients at high risk for developing specific irinotecan toxicity.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/12868555-
heal.journalNameJ Chemotheren
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate2003-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ